Caplin Point Laboratories has entered into a license and distribution agreement with Fresenius Kabi USA, LLC, a Delaware Limited Liability Company. Under this agreement, Caplin Point shall be responsible for developing and manufacturing identified parenteral products whereas Fresenius Kabi USA shall be holding these ANDAs and commercialize the same in USA. This is a product specific agreement for United States of America. Currently two products are featuring in the contract.
Caplin Point has already received milestone payments for two products and the product development cum dossier preparation have just commenced.
Fresenius Kabi is one of the leading global pharmaceutical companies with unique products and sharp focus on key geographies like USA and Europe.
